StockNews.AI
QNRX
StockNews.AI
1 min

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

1. Quoin Pharmaceuticals to release Q3 operational update on November 6, 2025. 2. Company focuses on rare and orphan diseases with four products in development. 3. Recent achievements may impact investor sentiment positively. 4. Key highlights include financial accomplishments and pipeline advancements.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive operational updates and achievements can lead to increased investor confidence, similar to previous instances where biopharma firms saw stock price surges after quarterly updates.

How important is it?

Operational updates can significantly influence stock performance, especially in specialty pharmaceutical firms, making this relevant for QNRX's future.

Why Short Term?

Q3 updates could lead to immediate market reactions, potentially influencing stock price shortly after November 6.

Related Companies

N/A
October 30, 2025 08:30 ET  | Source: Quoin Pharmaceuticals, Inc. ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com. For further information, contact:Quoin Pharmaceuticals Ltd.Michael Myers, Ph.D., CEOmmyers@quoinpharma.com  Investor RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com (646) 863-6341

Related News